Luneri

Vitamin E clinical brief

Vitamin E

Dossier live

Compound

CompoundStructured dossier pageDossier-backed

Compare alternatives Build protocol How this page is sourced

Publication state

Dossier live

Published from structured dossier data. Authored scoring and decision-tool promotion can be layered in later.

Dossier-backed

This page is grounded in structured dossier fields, with deterministic summaries layered on top for readability.

What it is for

Non-alcoholic steatohepatitis (NASH) - nondiabetic adults

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Highest-signal biomarkers

Human linked

AST

Hepatic and liver

Decrease

Grade A

ALP

Hepatic and liver

Decrease

Grade A

MDA

Oxidative stress

Decrease

Grade A

Research signal

Top caution

Drug interaction

Tocopherylquinone metabolite inhibits vitamin K-dependent carboxylase (VKOR); additive impairment of coagulation factor synthesis (II, VII, IX, X).

Dossier status

Dossier live

Published from dossier data; promoted scoring and decision-tool availability can be layered in later.

Meta-analyses

229

Pooled human evidence

RCTs

449

Randomized clinical trials

Tracked studies

925

Studies currently mapped to this dossier

Free previewDossier openingDerived

Preview summary

Clinical opening brief

How this is sourcedDerived

This executive summary is generated by application logic from structured dossier evidence and safety fields.

Vitamin E is a compound with its clearest current use in Non-alcoholic steatohepatitis (NASH) - nondiabetic adults.

This live dossier is anchored by 925 tracked studies, 229 meta-analyses, 449 RCTs and the clearest tracked movement in AST, ALP, MDA.

Tocopherylquinone metabolite inhibits vitamin K-dependent carboxylase (VKOR); additive impairment of coagulation factor synthesis (II, VII, IX, X). Tocopherylquinone metabolite inhibits vitamin K-dependent carboxylase (VKOR); additive impairment of coagulation factor synthesis (II, VII, IX, X). Cardiovascular Vitamin E use requires Hp genotype testing for risk stratification; not currently standard of care; applies primarily to diabetic patients with Hp2-2

Free dossier previewResearch access

Research unlocks the working sections of the brief

The clinical opening stays public. Research opens the deeper evidence, biomarker, dosing, and PGx layers once you want the full operating brief.

Overview

Mechanism, safety, and scope

The opening memo leads into the working sections where the compound gets pressure-tested before it belongs in a real protocol.

Mechanism summary, safety framing, and evidence-scope caveats continue here.

Synergies, contradictions, and unresolved questions sit alongside the overview before the tables begin.

Reading path

From memo into tables

Evidence rows show trial design, outcome direction, grading, and the specific claims that survived synthesis.

Biomarker groups, dosing protocols, and PGx notes sit behind the next layer once you need operational detail.

Evidence

Graded study rows

Trial design, endpoint direction, and confidence cues.

Biomarkers

Grouped outcome maps

Human-linked markers, dosing context, and cluster summaries.

Dosing

Protocol context

Use-case-specific doses, duration, and practical notes.

PGx

Actionable modifiers

Genes, interactions, and what actually changes practice.

Biomarker and evidence layer

Highest-signal biomarkers, evidence rows, and claim-by-claim grading live here once the dossier graduates from opening memo to working brief.

Current public view: Dossier live. Full access reveals the actual operating tables.

Protocol detail

Dosing schedules, form choices, and practical timing are held back until the compound is worth operationalizing.

PGx modifiers and safety friction stay in the same layer so the protocol decision is made in one pass, not by guesswork.

Research unlockPreview

Evidence, biomarkers, dosing, and PGx stay behind the glass

You are already inside the dossier. Upgrade when you need the full working sections instead of only the opening memo.